They will do Phase 2 again next year. This is because the current Phase 2 is for safety as they are using a higher dose.If OTO-413 has a positive outcome in their higher dose Phase 2a trial, have they stated if the next phase will be their pivotal phase?
That's a shame. It seems to be more effective than FX-322 from the results from their current clinical trials, but I do believe you need both to fix both hair cells and synapses.They will do Phase 2 again next year. This is because the current Phase 2 is for safety as they are using a higher dose.
New synapses are made in the brain all the time. Even taking some simple supplements or nootropics greatly aid in creating new synapses.synapses
Looks like this could be the end for Otonomy... so disappointing and depressing.OTO-413 failed at a higher dose.
Otonomy Reports Results from Clinical Evaluation of OTO-413 Higher Doses in Patients with Hearing Loss
Share price is down -60% on this news and down -95% since just before the news of OTO-313 failing.They probably lost most of their investors at this point.
I've been thinking about this recently about myself and could be possible but I do think we will have something good at least in our lifetime.living in a room with severe noxacusis the rest of my life.
It's believed that they contribute to the ability to hear clearly in noise. There are multiple synapses per hair cell, and they die off much sooner than hair cells. Having trouble hearing in noise is a chief complaint for people as they get older.I'm looking at the mechanism of action behind OTO-413, which got me wondering: why did Otonomy think that regenerating synapses could help with recovery from hearing loss, with nothing done to regenerate broken/dead hair cells? Seems pointless to me (keep in mind I have a limited understanding of how the inner ear works).
Maybe their technology could be combined with Frequency Therapeutics'? This is just wishful thinking on my part, I don't expect anything like this to happen.
They did mention this in their statement. It could work a lot better with lower doses.Wonder if the higher doses overdid it like the multi-dose FX-322. Anyways.
I am ready to end it all at this pointOTO-413 failed at a higher dose.
Otonomy Reports Results from Clinical Evaluation of OTO-413 Higher Doses in Patients with Hearing Loss
Which ones help?New synapses are made in the brain all the time. Even taking some simple supplements or nootropics greatly aid in creating new synapses.
Hope is all some of us have. I say don't listen to what others say if that's all they say. I try to be realistic about possibility and science is ALWAYS changing. And my mindset can't allow naysayers and the constant negativity to affect my life. My hearing does a great job of that itself. If I die with hope, it's better than living in misery because of listening to negativity.Like others say... don't get your hopes up.
I would be surprised if Otonomy isn't done after this. This is basically their 3rd strike. OTO-413's Phase 2a study data was promising, but with this higher dose study showing no benefit it throws that into question.Let's not get too negative with this guys; science is about experimentation, trial and error. They need to TRY things in order to get the optimal balance/dosage.
I think Otonomy will get there, they'll simply need to learn from this and figure it out.
It plays in to Frequency Therapeutics' hands though, I doubt anyone there is disappointed with this news.
Just try it on tinnitus sufferers already. What do they have to lose?What is next for OTO-413? Since the lower dose had more improvements, would they next go into a Phase 2b with the lower dose or have Otonomy given up and decided to not continue with OTO-413 any longer?
Lots of the racetams like Piracetam and Aniracetam do, Noopept too. The strongest one though by far, is Dihexa. But if you have even a small hint of cancer in your body, it will make it grow incredibly fast. The guy who created it accidentally spilled a huge amount of it into an open cut and said he had symptoms of autism for a few days after which would point to a huge amount of extra synapses. It wears off after you stop taking it though but some people have lasting effects.Which ones help?
I think their best hope is to try and partner up with a bigger biotech firm who will aid in funding the trials. A lot of smaller companies are doing this and especially more so now with how financial tightening is occurring. All the assets they hold are dropping quickly so they have even less cash.would they next go into a Phase 2b with the lower dose or have Otonomy given up and decided to not continue with OTO-413 any longer?
I've seen many people say they had relief from tinnitus with BDNF promoting supplements/nootropics so it does sound like at least some people would benefit from OTO-413.Just try it on tinnitus sufferers already. What do they have to lose?
How much money do Otonomy have left now? I think they should continue with OTO-413 but at a lower dose due to those improvements. I think that will be their final chance. If it does not work with more people at a lower dose, Otonomy will be done.I would be surprised if Otonomy isn't done after this. This is basically their 3rd strike. OTO-413's Phase 2a study data was promising, but with this higher dose study showing no benefit it throws that into question.
I doubt there's much celebration at Frequency Therapeutics' HQ. They weren't direct competitors with Otonomy, and OTO-413 would have complimented their offerings. The only direct threat Otonomy posed to Frequency Therapeutics was their OTO-6XX work, but now I wonder if that research will ever see the light of day.